| 000 | 01712 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517140948.0 | ||
| 264 | 0 | _c20170829 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1590-3729 | ||
| 024 | 7 |
_a10.1016/j.numecd.2016.12.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHeggen, E | |
| 245 | 0 | 0 |
_aSmoking cessation improves cardiometabolic risk in overweight and obese subjects treated with varenicline and dietary counseling. _h[electronic resource] |
| 260 |
_bNutrition, metabolism, and cardiovascular diseases : NMCD _cApr 2017 |
||
| 300 |
_a335-341 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aBlood Pressure |
| 650 | 0 | 4 | _aCounseling |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInsulin Resistance |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetabolic Syndrome _xdiagnosis |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNicotinic Agonists _xadverse effects |
| 650 | 0 | 4 |
_aNorway _xepidemiology |
| 650 | 0 | 4 |
_aObesity _xblood |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSmoking _xadverse effects |
| 650 | 0 | 4 |
_aSmoking Cessation _xmethods |
| 650 | 0 | 4 | _aSmoking Prevention |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriglycerides _xblood |
| 650 | 0 | 4 |
_aVarenicline _xadverse effects |
| 650 | 0 | 4 | _aWeight Loss |
| 700 | 1 | _aSvendsen, M | |
| 700 | 1 | _aTonstad, S | |
| 773 | 0 |
_tNutrition, metabolism, and cardiovascular diseases : NMCD _gvol. 27 _gno. 4 _gp. 335-341 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.numecd.2016.12.011 _zAvailable from publisher's website |
| 999 |
_c26895212 _d26895212 |
||